Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 12, 2004, Pages 2141-2147

  Berchuck, Andrew ^a   Schildkraut, Joellen M ^a   Wenham, Robert M ^a   Calingaert, Brian ^a   Ali, Shazia ^a   Henriott, Amy ^a   Halabi, Susan ^a   Rodriguez, Gustavo C ^a   Gertig, Dorota ^b   Purdie, David M ^c   Kelemen, Livia ^c   Spurdle, Amanda B ^c   Marks, Jeffrey ^a   Chenevix Trench, Georgia ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GESTAGEN; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ALLELE; ARTICLE; AUSTRALIA; CANCER EPIDEMIOLOGY; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DNA POLYMORPHISM; ENDOMETRIOID CARCINOMA; FEMALE; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 19944428552     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk. Collaborative analysis of twelve US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992;136:1184-203.
2. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-86.
3. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94: 32-8.
4. Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5:271-6.
5. Rodriguez GC, Nagarsheth NP, Lee KL, et al. Progestin-induced apoptosis in the macaque ovarian epithelium: differential regulation of transforming growth factor-β. J Natl Cancer Inst 2002;94:50-60.
6. McKenna NJ, Kieback DG, Carney DN, Fanning M, McLinden J, Headon, DRA. Germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. Br J Cancer 1995;71:451-5.
7. Rowe SM, Coughlan SJ, McKenna NJ, et al. Ovarian carcinoma-associated TacjI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res 1995;55:2743-5.
8. Lancaster JM, Berchuck A, Carney M, Wiseman RW, Taylor JA. Progesterone receptor gene polymorphism and risk of breast and ovarian cancer. Br J Cancer 1998;78:277.
9. Manolitsas TP, Englefield P, Eccles DM, Campbell IG. No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Br J Cancer 1997;75; 1398-9.
10. Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis 2001;22:717-21.
11. Tong D, Fabjani G, Heinze G, Obermair A, Leodolter S, Zeillinger R. Analysis of the human progesterone receptor gene polymorphism PROGINS in Austrian ovarian carcinoma patients. Int J Cancer 2001; 95:394-7.
12. Lancaster JM, Wenham RM, Halabi S, et al. No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. Cancer Epidemiol Biomarkers Prev 2003;12:226-7.
13. De Vivo I, Huggins GS, Hankinson SE, et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A 2002;99:12263-8.
14. Jacobsen BM, Richer JK, Schittone SA, Horwitz KB. New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem 2002; 277:27793-800.
15. Richer JK, Jacobsen BM, Manning NG, Abel, MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002; 277:5209-18.
16. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 2000;20:3102-15.
17. DeVivo I, Hankinson SE, Colditz GA, Hunter DJA. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res 2003;63:5236-8.
18. Spurdle AB, Purdie D, Chen X, Chenevix-Trench G. The prohibirin 3′ untranslated region polymorphism is not associated with risk of ovarian cancer. Cancer Res 2003;90:145-9.
19. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 2003;89:280-94.
20. Schildkraut JM, Thompson WD. Familial ovarian cancer: a population-based case-control study. Am J Epidemiol 1988;128:456-66.
21. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
22. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
23. Thomas DC, Witte JS. Point: population stratification: a problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomarkers Prev 2002;11:505-12.
24. Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Cancer Res 1997;64:196-206.
25. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003;349:1443-50.
26. Li AJ, Baldwin RL, Karlan BY. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstet Gynecol 2003;189:22-7.
27. Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab 2000;85:2897-2902.
28. Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 2002;72:163-72.
29. Mote PA, Balleine RL, McGowan EM, Clarke CL. Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 1999;84:2963-71.